Welcome to the inaugural edition of ‘Obesity Wire’, a dedicated newsletter designed to equip healthcare providers with the latest advancements, best practices, and transformative insights in the field of obesity and metabolic care.
As providers on the front lines of healthcare, you play a crucial role in addressing the multifaceted challenges posed by obesity.
This newsletter aims to support you with evidence-based strategies, clinical updates, and practical tools to enhance your approach to obesity management. From groundbreaking research findings to patient-centered treatment approaches, ‘Obesity Wire’ is your go-to resource for staying informed and empowered in delivering optimal care.
Each edition will feature summaries of recent studies, expert interviews, practical tips for counseling patients, and updates on innovative treatments. Our goal is to foster a community where knowledge exchange and collaboration thrive, ultimately improving outcomes for patients struggling with obesity.
In this issue, you’ll find:
- Latest Evidence: Summaries of groundbreaking studies and how you can apply the evidence in your practice.
- Practice Transformation and Value-based Care: Practical tips and strategies for transforming your practice, whether it is cash-based, fee-for-service, or value-based care.
- VC, Startup, and Tech Updates: Highlights from the latest venture capital investments in obesity telehealth, featuring Form Health’s successful funding round.
- Featured Practices and Founders: Mission-driven stories of practices and founders and the impact they are creating in the field of obesity.
- Events: Information on upcoming conferences such as Obesity Week 2024 and the World Obesity Weight Management Conferences 2024.
Thank you for joining us on this journey to advance obesity care. Together, we can make a meaningful difference in the lives of our patients and contribute to the broader effort of combating obesity-related health challenges.
We are excited to announce our waitlist for becoming a member of our exclusive Obesity Provider Community.
As a member, you’ll enjoy early access to free and discounted tools designed to enhance your obesity care practice. Membership is currently free!
New Brain Targets for GLP1-based Obesity Drugs May Reduce Weight Without Nausea
Key Findings
- New Brain Targets: Researchers have identified specific brain regions that can be targeted by these drugs to enhance their weight loss effects without inducing nausea. The study highlights the potential of focusing on the hindbrain and hypothalamus.
- Mechanism of Action: By targeting these areas, the drugs can modulate appetite and energy expenditure more precisely, reducing the unpleasant side effects that often accompany GLP1-based therapies.
- Study Evidence: Preclinical trials in animal models showed that modifying the drug’s action to avoid certain brain regions could lead to significant weight loss without nausea, suggesting a path for developing better-tolerated obesity treatments.
These findings offer a breakthrough in obesity treatment by potentially providing a way to harness the benefits of GLP1 receptor agonists without the drawbacks. Improved patient tolerance could lead to higher adherence rates and better overall health outcomes for those struggling with obesity.
Beyond Blood Sugar: How Diabetes Drugs Like Ozempic Could Lower Cancer and Obesity Risks
Recent research highlighted in Medical News Today suggests that certain diabetes medications, including Ozempic, may offer additional health benefits beyond blood sugar control. These drugs could potentially reduce the risks of cancer, offering new hope for comprehensive disease management.
Key Findings
- Medications in Focus: The study examines the effects of GLP-1 receptor agonists, a class of diabetes drugs that includes Ozempic (semaglutide), on cancer and obesity risks.
- Cancer Risk Reduction: Evidence indicates that GLP-1 receptor agonists may help lower the risk of certain cancers, particularly colorectal and pancreatic cancers. The mechanisms behind this protective effect are thought to involve improved insulin sensitivity and reduced inflammation.
- Study Evidence: The conclusions are drawn from a combination of clinical trials and observational studies, suggesting a strong potential for these drugs to be repurposed for broader health benefits.
Implications
The potential for GLP-1 receptor agonists to reduce cancer marks a significant advancement in the treatment of obesity and related conditions. These findings suggest that patients using these medications could enjoy additional protective health benefits, leading to improved overall outcomes.
Pfizer’s New Obesity Drug Danuglipron Shows Promise in Weight Loss
Pfizer is making headlines with its new daily medication, Danuglipron, aimed at combating obesity. This innovative drug has shown promising results in clinical trials, offering a new hope for effective weight management.
Key Findings
- Danuglipron Overview: Danuglipron is a GLP-1 receptor agonist designed to help patients manage their weight by regulating appetite and promoting feelings of fullness.
- Mechanism of Action: Similar to other GLP-1 receptor agonists, Danuglipron works by mimicking the hormone GLP-1, which plays a key role in controlling hunger and food intake. This helps reduce caloric intake and supports weight loss.
- Daily Administration: Unlike some weight loss treatments that require weekly injections, Danuglipron is administered daily in pill form, potentially improving patient compliance and convenience.
Implications
The development of Danuglipron represents a significant advancement in the fight against obesity. Its daily oral administration and promising trial results suggest it could become a widely adopted treatment, providing an effective and user-friendly option for weight management.
Discovery of Obesity Gene Offers New Insights into Brain Activity Regulation
A recent study published by Neuroscience News has identified a gene linked to obesity that also plays a crucial role in regulating brain activity. This groundbreaking discovery provides new perspectives on the genetic factors influencing both body weight and brain function.
Key Findings
- Obesity-Linked Gene: Researchers have pinpointed a specific gene- SH2B1 gene associated with obesity that impacts brain activity. This gene, when mutated, can influence both weight gain and neurological processes.
- Brain Activity Regulation: The study reveals that the gene in question affects synaptic plasticity, which is essential for learning, memory, and overall cognitive function. Alterations in this gene can lead to changes in brain activity patterns.
- Mechanistic Insights: The gene’s influence on both metabolism and brain function suggests a complex interplay between genetic factors and physiological processes. This dual role could explain why certain individuals are more prone to obesity and its related cognitive effects.
- Research Methods: Using advanced genetic sequencing and brain imaging techniques, the researchers analyzed the gene’s effects in both animal models and human subjects. This comprehensive approach allowed for a detailed understanding of how the gene operates.
Implications
The identification of an obesity-linked gene that regulates brain activity opens new avenues for treating obesity and its associated cognitive impairments. By targeting this gene, future therapies could address both weight management and brain health, offering a holistic approach to obesity treatment.
Clinical Best Practices
Effective obesity care requires a multidisciplinary approach. As healthcare providers, it’s essential to work with registered dietitians, exercise physiologists, and mental health professionals to develop comprehensive treatment plans that address the physical, emotional, and social aspects of obesity.
Key Takeaways:
- Involve patients in the goal-setting process to increase motivation and adherence to treatment plans.
- Use evidence-based guidelines to develop personalized treatment plans that address the unique needs of each patient.
- Consider referring patients to behavioral health professionals to address underlying emotional and psychological factors that contribute to obesity.
Best practices suggest that appropriate lifestyle interventions in obesity management should consist of a high-intensity intervention (i.e., 14 sessions or more for 6 months) including dietary and physical activity interventions as well as behavioral intervention by trained interventionists (e.g., behavioral therapist, psychologist, psychiatrist). Treatment for obesity should also be viewed as a long-term endeavor that will require management for the rest of the patient’s life and not a one-time intervention (e.g., ‘go on a diet’).
Value-Based Care
A Viewpoint commentary for JAMA Internal Medicine by LDI Senior Fellows Amol Navathe and Ezekiel Emanuel, with Daniel Shenfeld from the Perelman School of Medicine, lists critical challenges—with solutions—to achieving VBP goals.
- Health care organizations must be able to lower costs without reducing revenue.
- CMS should revise risk adjustment to eliminate ‘ghost savings’.
- CMS should support the VBP transition with technical help.
VC and Tech
Obesity Telehealth Startup Form Health Raises $38 Million for it’s Series by Venture capital firm Sound Ventures, which was co-founded by actor Ashton Kutcher, led the round. Venture capital firms SignalFire, M13 and Next View Ventures also participated.
- The obesity telehealth space is still attracting investors with the rise of GLP-1 demand, the company is working with big pharmaceutical company Eli Lilly through its direct-to-consumer telehealth service called LillyDirect.
AI in Obesity Care?
Taken from ‘Artificial Intelligence and Obesity Management: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023
- AI applications such as chatbots may assist clinicians by answering queries and performing tasks such as writings, publications, as well as drafting office or institutional Policies and Procedures and Standard Operating Procedures.
- AI may help clinicians by offering interactive programming related to analyses of body composition imaging for more accurate assessment of anthropometrics, behavior coaching, personal nutritional intervention & physical activity recommendations, predictive modeling for identifying patients at risk for obesity-related complications, and implementation of precision/personalized medicine, where treatment is optimized based upon a patients clinical presentation and genetic makeup.
- AI may augment telemedicine, with tasks ranging from scheduling of appointments to integrating remote monitoring of patients (e.g., wearable technologies and mobile applications).
“AI chatbots should be designed to be human-like, personalized, contextualized, immersive, and enjoyable to enhance user experience, engagement, behavior change, and weight loss. These require the integration of health metrics (e.g., based on self-reports and wearable trackers), personality and preferences (e.g., based on goal achievements), circumstantial behaviors (e.g., trigger-based overconsumption), and emotional states (e.g., chatbot conversations and wearable stress detectors) to deliver personalized and effective recommendations for weight loss”
Behavior Coaching- The Future?
AI assessment of a patient’s individual behavior, actions, thoughts, and emotions may help identify patterns that may help direct personalized coaching. AI-medicated patient-centered recommendations may better help patients achieve their goals. Through an assessment of patient data, AI predictive modeling may identify areas of greatest need of improvement and interventions most likely to achieve favorable health outcomes. Such an assessment may include and integrate input data from: (a) self-reports via questionnaires, (b) medical health records, (c) self-monitoring devices and health trackers, and (d) conversational and wearable stress detectors that may provide insight into behaviors, preferences, and emotional states. Once data is assimilated and integrated, then virtual coaching assistants may provide personalized answers to patient questions, contribute to individualized feedback, relate evidence-based guidance, and provide general support.
Through natural language conversations with users, AI chatbots can provide real time adaptive recommendations which include decision-making and self-regulation skills, progress feedback to reach certain weight loss goals, and emotional support with motivation and validation.
Overall, AI chatbots may help optimize weight loss and can deliver personalized and effective recommendations for weight loss programs . In addition to weight reduction, consistent with the general principle that optimal behavior modification involves continuous monitoring and engagement, AI reinforced learning via continuously-monitored digital data may help optimize weight loss and weight loss maintenance. AI with chatbots programmed with simulated empathy may further help promote long-term weight management. Finally, AI gamification techniques may help make behavior coaching more engaging and fun (e.g., setting up challenges, establishing rewards, and creation of other incentives to motivate individuals to achieve their goals). Such promising emergent AI-related technologies. Benefits of AI-mediated gaming extend to reduced caloric consumption (and improved cardiopulmonary function) among younger individuals with obesity.
Events
Obesity Week 2024
This conference in San Antonio, Texas from November 2–6, 2024, covers the entire spectrum of obesity science, including research, clinical applications, public policy, diet, exercise, lifestyle, psychology, and medical and surgical interventions.
World Obesity Weight Management Conferences 2024
This conference in Baltimore, Maryland from October 24–26, 2024, is hosted by Magnus Group.
The Obesity Summit: Obesity + Women’s Health (OMASummit24)
This two-day conference in Isle of Palms, SC, organized by the Obesity Medicine Association in partnership with women’s health experts, will take place in August 2024. It will explore gender-specific health disparities, chronic disease management, and holistic obesity treatment approaches for women. Registration opens in August 2024.
Obesity Medicine Conference 2025
OMA Annual Conference National Harbor, MD | April 23-27, 2025 The Obesity Medicine Association is now accepting presentation proposals for Obesity Medicine 2025, aimed at obesity medicine clinicians. The conference will focus on enhancing foundational knowledge and skills in obesity medicine, with an emphasis on practical applications in physical activity and nutrition. Submit your proposal today!
Resources
Thank you for taking the time to read this edition of Obesity Wire. We hope you found the information valuable and inspiring as you continue to provide exceptional care for your patients.
We invite you to join our community waitlist to stay connected with fellow healthcare professionals dedicated to advancing obesity care. Don’t forget to subscribe to our newsletter for the latest updates and insights, and share it with your colleagues who might benefit from this resource.